AGC Inc

AGC Inc. faces board‑independence scrutiny amid rising capital‑expenditure demands for Industry 4.0 tech, while India’s market dynamics and investor trends shape funding for sustainable glass‑manufacturing growth.

AGC Biologics expands manufacturing in Yokohama, partners with Novelty Nobility to launch a bispecific antibody for retinal disease, tapping a 7.8 % APAC specialty‑drug boom and rising consumer willingness to spend on sustainable, tech‑driven health…

AGC Biologics earns 2026 Fierce Outsourcing Award for regulatory excellence, poised to grow its global CDM footprint with new Yokohama plant, AI‑driven quality, and strategic partnerships.

AGC Biologics has solidified its position in the biopharmaceutical industry through a strategic partnership with Quell Therapeutics, but its stock price has experienced volatility and its valuation multiples raise concerns.